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Abstract
Purpose The purpose of this study was to compare three dif-
ferent biopsy devices on false-negative and underestimation
rates in MR-guided, vacuum-assisted breast biopsy (VABB)
of MRI-only lesions.
Methods This retrospective, single-center study was IRB-ap-
proved. Informed consent was waived. 467 consecutive pa-
tients underwent 487 MR-guided VABB using three different
8-10-gauge-VABB devices (Atec-9-gauge,A; Mammotome-
8-gauge,M; Vacora-10-gauge,V). VABB data (lesion-type,
size, biopsy device, histopathology) were compared to final
diagnosis (surgery, n= 210 and follow-up, n= 277). Chi-
square, and Kruskal–Wallis tests were applied. P values<0.05
were considered significant.
Results Final diagnosis was malignant in 104 (21.4 %), high
risk in 64 (13.1 %) and benign in 319 (65.5 %) cases. Eleven
of 328 (3.4 %) benign-rated lesions were false-negative (1/95,
1.1 %, A; 2/73, 2.7 %, M; 8/160 5.0 % V; P=0.095). Eleven
high-risk (11/77, 14.3 %) lesions proved to be malignant (3/
26, 11.5 % A; 4/12, 33.3 % M; 4/39, 10.3 % V; P=0.228).
Five of 34 (14.7 %) DCIS were upgraded to invasive cancer
(2/15, 13.3 %, A; 1/6, 16.6 % M; 2/13, 15.3 %, V; P=0.977).
Lesion size (P=0.05) and type (mass vs. non-mass, P=0.107)
did not differ significantly.
Conclusion MR-guided VABB is an accurate method for di-
agnosis of MRI-only lesions. No significant differences on
false-negative and underestimation rates were observed be-
tween three different biopsy devices.
Key Points
•MR-guided VABB is an accurate procedure for the diagnosis
of MRI-only lesions.
• Similar false-negative and underestimation rates allow all three
different MR-guided VABB devices for clinical application.
• High-risk lesions should undergo surgery due to a substan-
tial underestimation rate.
• Agreement between MR-guided VABB and final diagnosis
(benign/malignant) was 95.5% (465/487).
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Introduction
Contrast-enhanced magnetic resonance imaging (CE-MRI) is
the most sensitive method for the detection of breast cancer [1,
2]. The high sensitivity leads to detection of lesions visible
only on breast MRI. MRI-only lesions are defined as lesions
that cannot be detected by other imaging modalities, including
second-look (MRI directed) ultrasound [3]. In case of a sus-
picious MRI-only lesion, histological verification with MR-
guided VABB is mandatory [4, 5].
It has been shown that MR-guided vacuum-assisted breast
biopsies (VABB) are a fast, safe, and accurate method that
cause only minimal scarring and no consecutive breast defor-
mity compared to surgical breast biopsy [6–20]. However, re-
ported cancer detection, as well as false-negative and underes-
timation rates using MR-guided VABB, vary considerably
among previously published studies [6–20]. These differences
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can only be partly explained by different study designs and
patient populations. The influence of the MR-guided VABB
device used, as well as the needle size, on false-negative and
underestimation rates still remains unclear, as studies compar-
ing individual devices have not yet been performed. To address
this issue, a comparative study of several MRI-guided VABB
devices using standardized conditions is warranted.
The purpose of this study was to compare three different
biopsy devices on false-negative and underestimation rates in
MR-guided VABB of MRI-only lesions.
Materials and methods
Study design
This retrospective single-center study was institutional review
board (IRB)-approved and informed consent was waived. In
our tertiary care breast cancer assessment center, we collected
data from the institutional database for all consecutive women
with non-palpableMRI breast lesions that were occult both on
mammography and ultrasound, and for whom successful MR-
guided biopsy was performed due to suspicious (BI-RADS 4
or 5) findings on CE-MRI. MRI-only cases were included in
which a final diagnosis had been established either by open
surgery, in case of malignant and high-risk lesions, or imaging
follow-up, in case of benign lesions. Aminimum of 12months
imaging follow-up, to establish a standard of reference, has
been applied [21, 22].
There were 467 consecutive patients (mean age 52, range
18–87 years) who underwent 487 MR-guided biopsies in our
department during 11/2006 to 7/2013 and who were included
in this study (Fig. 1).
MR-guided biopsy
All MR-guided biopsies were performed on a 1.5-Tesla (T)
system (Magnetom Avanto, Siemens Medical Solutions®,
Erlangen, Germany) using a dedicated double breast imaging
and intervention coil (InVivo, Philips, Netherlands). A short
imaging protocol for lesion localization, consisting of a dynam-
ic contrast-enhanced T1-weighted, spoiled gradient echo (fast
low angle shot, FLASH-3D) sequence [repetition time/echo
time (TR/TE) 11/4.76 ms; spatial resolution 0.7×0.7×3 mm;
64 slices; acquisition time 58 sec] was acquired before and
repeated once or twice after the intravenous (IV) application
of 0.15 mmol/kg body weight of Gd-DOTA (Dotarem,
Guerbet, France) with an automatic injector (Spectris,
Medrad, Germany) at 3 ml/s. Automatically scaled subtraction
images were obtained by subtracting pre-contrast images from
post-contrast images using the vendor-supplied software.
Intervention planning was performed without additional
software by manually referencing the MRI lesion localization
to that of anMRI-compatiblemarker with positive T1-weighted
contrast. After obtaining written, informed consent for the pro-
cedure, vacuum-assisted biopsy using three different 8- to 10-
gauge devices (Vacora [V], Bard Biopsy Systems, Tampa,
USA; Mammotome [M], Devicor Medical Products,
Cincinnati, USA; or ATEC [A], Hologic, Indianapolis, USA)
was performed by one of four experienced, board-certified ra-
diologists (T.H.H., K.P, P.K., B.A.T.). The following needles
were used for A (9-gauge Atec MRI needle, Hologic,
Indianapolis, USA), M (8-gauge MRI needle, Devicor
Medical Products, Cincinnati, USA), V (10-gaugeMRI needle,
Bard Biopsy Systems, Tampa, USA). The following markers
were used for A (Atec TriMark, Hologic), M (Mammomark
3.5 mm, Devicor Medical Products) and V (BiomarC
1×5 mm, Carbon Medical Technologies, MI, USA). M and
A are MR-guided, console-based vacuum biopsy systems,
whereas V is a hand-held vacuum biopsy system. All radiolo-
gists performed at least 20 MR-guided biopsies with each re-
spective device. One radiologist who had performed more than
200MR-guided biopsies in different institutions using different
devices supervised the first 15 cases of the other 3 radiologists.
The selection of each device was based solely on its availability
during the study period and never on lesion type or needle size.
The FLASH-3D sequence above was repeated to verify nee-
dle positioning during the procedure. The number of samples
obtained was 12–24, depending on lesion size and location
[23]. The biopsy site was marked with MRI-compatible clip
markers. To verify biopsy site and clip position and to exclude
potential complications, such as major bleeding, a final
FLASH-3D sequence was obtained. The results of histopatho-
logical analysis, which was performed by an experienced,
board-certified breast pathologist (M.R.), were compared with
the MR imaging results in interdisciplinary consensus. The B
classification was applied for histological diagnosis [24]. In
cases of discrepancy between imaging and histopathology,
and in case of lesions with uncertain malignant potential (B3),
open biopsy was performed after wire localization by board-
certified, experienced breast surgeons. In case of a benign find-
ing, there was MR imaging follow-up of at least 12 months.
Reasons for surgery on a benignVABB result were suspicion of
poor targeting, e.g. epithelial hyperplasia without atypia as his-
tological diagnosis on MR-guided VABB when a solid mass
lesion was seen on MRI — such findings are deemed discrep-
ant and usually undergo surgery in our department.
Data analysis
Standard of reference
MR-guided VABB data were obtained, including lesion type,
size, biopsy device, and histopathology. The standard of ref-
erence final diagnosis (benign or malignant), was derived
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from surgery (n=210; histopathology subtype diagnosis: be-
nign, high-risk, ductal carcinoma in situ [DCIS], invasive can-
cer [IC]) or imaging follow-up (n=277) of at least 12 months.
Data analysis followed the methodology established in a prior
investigation [25].
Association of MR-guided VABB results and standard
of reference
Agreement or discrepancies between MR-guided VABB results
regarding final diagnosis (benign and malignant) and subtype
diagnosis (benign, high-risk, DCIS, IC) were documented. A
VABB/imaging discrepancy was defined as a discrepancy be-
tween imaging and VABB results. If, e.g. pathology described
general tissue changes (fibrosis, unspecific epithelial hyperplasia)
in case of a circumscribed enhancing lesion, this was deemed as
not consistent with imaging findings. MR-guided VABB cases
without a change of final diagnosis (benign and malignant) but
with a different subtype diagnosis are reported separately.
High-risk lesion underestimation rate
High-risk lesions were atypical ductal hyperplasia (ADH),
lobular carcinoma in situ (LCIS), papillary lesions (intraductal
papilloma and papilloma with atypia), radial scar, and phyl-
lodes tumour [25]. High-risk lesions that were diagnosed at
MR-guided VABB, and in which a subsequent diagnosis of
invasive cancer or DCIS lesion was made at surgical excision,
were considered underestimates, after multidisciplinary re-
view [26]. The high-risk lesion underestimation rate was de-
fined as the number of these underestimated lesions divided
by all high-risk lesions at MR-guided VABB histologic exam-
ination [27]. The final diagnosis (benign versus malignant)
served as a reference standard for underestimation-rates.
MR-guided VABB cases without a change of final diagnosis
(benign and malignant) but with a different subtype diagnosis
are reported separately.
False-negative rate
A false-negative result was considered a pathologically prov-
en malignancy in which MR-guided VABB yielded benign
findings. The false-negative rate was defined as the number
of false-negative cases divided by the number of patients with
cancer diagnosed.
Statistical analysis
Statistical analysis was performed using SPSS 20 (IBM,
Chicago, USA) and Medcalc 12.7.5.0 (Mariakerke,
Belgium). Descriptive statistics included calculation of the
mean, standard deviation (SD), and 95 % confidence intervals
(95 % CI).
To assess the association of the different MR-guided
VABB devices with underestimation and false-negative biop-
sy rates, a Chi-square test was used.
Continuous variables distribution was assessed by a
Kolmogorov–Smirnoff test and compared by non parametric
tests (Kruskal–Wallis) as the normal distribution was not ver-
ified. P values of 0.05 or less were considered to indicate a
statistically significant result.
Note.
* cases were considered false-negative, resulting in a false-negative rate of 10.6% (11/104)
** high-risk underestimation rate
VABB, vacuum–assisted breast biopsy DCIS, ductal carcinoma in situ.
Fig. 1 Study design flowchart
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Results
Characteristics of study population
The median size of 487 MR-guided, VABB-proven breast
lesions was 15.78 mm (range, 3–76 mm). Between three dif-
ferent MR-guided VABB devices, lesion size did not differ
significantly (P=0.05). The distribution rates among the 3
MR-guided VABB devices were as follows: 157/487
(32.2 %, A); 101/487 (20.7 %, M); and 229/487 (47 %, V).
Patient age did not differ significantly among the three MR-
guided VABB devices (P=0.112). Final diagnosis was malig-
nant in 104 (21.4 %) and benign in 383 (78.6 %). The distri-
bution of mass and non-mass lesions between the three MR-
guided VABB devices was: 122/229 were mass lesions in V
(53.3 %); 68/101 in M (67.3 %); and 89/157 in A (56.7 %;
P=0.107).
MR-guided VABB results
The histologic examination at MR-guided VABB yielded 48
of 487 (9.9 %) invasive carcinomas, 34 of 487 (7.0 %) DCIS
lesions, 77 of 487 (15.8 %) high-risk lesions, and 328 of 487
(67.4 %) benign lesions. Agreement between MR-guided
VABB results regarding exact final subtype diagnosis
(benign, high-risk, DCIS, IC) was achieved in 448 of 487
(91.9 %; Table 1). In accordance with the standard of refer-
ence agreement between MR-guided VABB results and the
final diagnosis (benign and malignant) was achieved in 465
of 487 (95.5 %) cases. MRI-guided VABB results and final
diagnosis stratified by biopsy devices are shown in Table 2.
Eighty-two of 104 (78.9 %) surgery-proven cancers were
diagnosed by the initial MR-guided VABB. The distributions
of malignant lesions between the 3MR-guided VABB devices
were as follows: 36/157 (22.9 %) A; 16/101 (15.8 %) M; 30/
229 (13.1 %) V; P=0.103. In five of 34 (14.7 %) VABB-
proven DCIS lesions, diagnosis was upgraded to invasive
cancer by surgery (2/15, 13.3 %, A; 1/6, 16.6 % M; 2/13,
15.3 %, V; P=0.977; Tables 1 and 2). There were no false-
positive findings.
Thirty-five of 328 (10.7 %) benign lesions at MR-guided
biopsy were confirmed by surgery (Table 1, Fig. 1). In five of
328 (1.5 %) lesions, MR-guided VABB diagnosed a benign
lesion, and there was an up-grade based on surgery to a high-
risk lesion, but not to cancer. All other 277 (84.5 %) benign
MR-guided VABBwere stable during a follow-up period of at
least 12 months (median 44, range 12–92 months).
Histopathological diagnoses are summarized in Table 3.
High-risk lesion underestimation rates
Eleven high-risk lesions were upgraded to cancer at surgery
(seven invasive carcinomas, four DCIS lesions; Table 1,
Figs. 1 and 2), resulting in a high-risk underestimation rate
of 14.3 % (11/77, 95 % CI: 7.9–23.9 %). The distributions of
all upgraded high-risk lesions among the 3MR-guided VABB
devices were as follows: 3/26 (11.5 %) A; 4/12 (33.3 %)M; 4/
39 (10.3 %) V; P=0.228 (Table 2). Seven (9.1 %, 7/77) high-
risk lesions were confirmed as benign by surgery.
False-negative rates
Eleven of 328 (3.4 %) benign-rated lesions were false-nega-
tive, resulting in a negative predictive value (NPV) of 96.6 %
(317/328, 95%CI: 94.1–98.3%). False-negative lesions were
distributed among the three MR-guided VABB devices as
follows: 1/95 (1.1 %) A; 2/73 (2.7 %) M; 8/160 (5.0 %) V;
P=0.095. The resulting false-negative rate was 10.6 % (11/
104, 95 % CI: 5.8–18.1 %; 1/40 (2.5 %) A; 2/22 (9.1 %)M; 8/
42 (19.0 %); P=0.0611; Tables 1 and 2, Fig. 1).
Eight of eleven (66.7 %) false-negative lesions were mass
lesions. Characteristics of false-negatives are shown in
Table 4. All eleven false-negative lesions were identified as
discordant findings between imaging and MR-guided VABB
results (Table 4, Fig. 3). The median size of the eleven false-
negative lesions was 11.5 mm (range, 5–60 mm). Numerical
Table 1 MR-guided VABB
results and final diagnosis Final diagnosis Biopsy results Total
Benign High-risk DCIS Invasive cancer
Benign 312 (97.8) 7 (2.2) 0 (0) 0 (0) 319 (100)
High-risk 5 (7.8) 59 (92.2) 0 (0) 0 (0) 64 (100)
DCIS 1 (2.9) 4 (11.8) 29 (85.3) 0 (0) 34 (100)
Invasive cancer 10 (14.3) 7 (10.0) 5 (7.1) 48 (68.6) 70 (100)
Total 328 (67.4) 77 (15.8) 34 (7.0) 48 (9.9) 487 (100)
Note: Numbers in parentheses are percentages
DCIS, ductal carcinoma in situ
VABB, vacuum assisted breast biopsy
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differences between the three MR-guided VABB devices did
not reach significance (Table 2).
Discussion
The results of our study show no influence of three different
biopsy devices on false-negative and underestimation rates in
MR-guided VABB of MRI-only lesions. Our results confirm
that MR-guided VABB is an accurate procedure for histopath-
ologic verification of MRI-only lesions according to the stan-
dard of reference (surgery and follow-up). In accordance with
the standard of reference, agreement between MR-guided
VABB results and the final diagnosis (benign and malignant)
was achieved in 465 of 487 (95.5 %).
Currently, there are several MR-guided VABB devices com-
mercially available. The devices show minor variations in han-
dling and needle size. MR-guided VABB has shown to be ad-
vantageous over large-core needle biopsy [28]. Several studies
provide evidence that MR-guided VABB is an accurate method.
In these studies, false-negative and underestimation rates ranged
from 0–17 % and 0–100 %, respectively [6–18, 20, 29]. The
considerable differences seem to be caused by multiple factors,
such as differences in investigating institutions, operators, VABB
devices, and histopathological work-up.
We did not identify an influence of biopsy device on
false-negative and underestimation rates among the three
different MR-guided VABB devices. All MR-guided
VABB in this comparative analysis were performed
within one institution under standardized conditions by
the same experienced radiologists, and the same experi-
enced breast pathologist assessed the results. Therefore,
we minimized possible factors that might have led to
the previously reported differences in the performance
of MR-guided VABB. In addition, our results did not
confirm the findings from a previous study, which
showed that an MR-guided, console-based, vacuum bi-
opsy system differs from a hand-held vacuum biopsy
system, and allows smaller lesions to be biopsied with
higher operator confidence [16].
In our study, it was shown that accurate MR-guided VABB
results are obtained regardless of the biopsy device used.
The false-negative rate of 10.6 % (11 out of 104) in our
study is acceptable compared to previously reported false-
negative rates ranging from 0–17 % [6, 7, 13, 16]. All false-
negative findings were correctly identified due to radio-
histopathological discordance. Consequently, no cancer was
Table 2 Correlation of MR-
guided VABB results and final
diagnosis stratified by biopsy
device
Final diagnosis Biopsy results Total
Benign High-risk DCIS Invasive cancer
Vacora 10G
Benign 148 (99.3) 1 (0.7) 0 (0) 0 (0) 149 (100)
High-risk 4 (10.5) 34 (89.5) 0( 0) 0 (0) 38 (100)
DCIS 1 (6.7) 3 (20.0) 11 (73.3) 0 (0) 15 (100)
Invasive cancer 7 (25.9) 1 (3.7) 2 (7.4) 17 (63.0) 27 (100)
Total 160 (69.9) 39 (17.0) 13 (5.7) 17 (7.4) 229 (100)
Mammotome 8G
Benign 70 (98.6) 1 (1.4) 0 (0) 0 (0) 71 (100)
High-risk 1 (12.5) 7 (87.5) 0 (0) 0 (0) 8 (100)
DCIS 0 (0) 1 (16.7) 5 (83.3) 0 (0) 6 (100)
Invasive cancer 2 (12.5) 3 (18.8) 1 (6.3) 10 (62.5) 16 (100)
Total 73 (72.3) 12 (11.9) 6 (5.9) 10 (9.9) 101 (100)
Atec 9G
Benign 94 (94.9) 5 (5.1) 0 (0) 0 (0) 99 (100)
High-risk 0 (0) 18 (100) 0 (0) 0 (0) 18 (100)
DCIS 0 (0) 0 (0) 13 (100) 0 (0) 13 (100)
Invasive cancer 1 (3.7) 3 (11.1) 2 (7.4) 21 (77.8) 27(100)
Total 95 (60.5) 26 (16.6) 15 (9.6) 21 (13.4) 157(100)
Note: Numbers in parentheses are percentages
DCIS, ductal carcinoma in situ
G, gauge
VABB, vacuum assisted breast biopsy
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missed and patients were treated in appropriate time frames.
This underlines the importance of regular multidisciplinary
conferences to discuss image-guided biopsy findings and to
avoid false-negative results. Importantly, MR-guided VABB
showed a high NPVof 96.6 %.
MR-guided VABB revealed high-risk lesions in 16 % (77
out of 487) of the biopsied lesions. In previous studies, there
were varied reported underestimation rates, up to 100 % [6–8,
11–14, 17–19]. The underestimation rate in our study is well
within the lower range of reported underestimation rates in
MR-guided VABB, ranging from 13–50 % [20] .
Nevertheless, our results highlight the necessity for surgical
biopsy of high-risk lesions revealed by MR-guided VABB to
avoid missing breast cancer.
Although in agreement with previously published results,
the malignancy rate in the current study was rather low. This
can be explained by the composition of our patient collective
in our tertiary care breast cancer assessment center. Patients
either had an imaging abnormality when they presented for
assessment or were high-risk patients who presented for
screening. In screening, the prevalence of malignancy is low,
leading to a proportionally higher number of false-positive
findings. Furthermore, second-look (MRI-directed) ultra-
sound was subsequently performed in our department to lo-
calize MRI-detected lesions. In cases of successful second-
look ultrasound, further workup can then be performed under
ultrasound guidance. Ultrasound-guided biopsies are, in gen-
eral, desirable, as they are less costly, readily available, and
more comfortable for the patient [2, 25]. A recent meta-
analysis on the utility of second-look ultrasound demonstrated
Table 3 Characteristics of 487 MR-guided VABB results compared
with the final diagnosis
Final diagnosis Biopsy results Total
Benign High-risk DCIS Invasive cancer
Malignant 11 11 34 48 104
High-risk lesion 5 59 0 0 64
Fibroadenoma 19 0 0 0 19
Scar 7 0 0 0 7
Fibrocystic disease 158 3 0 0 161
Inflammation 11 0 0 0 11
Unspecific 60 0 0 0 60
FAH 31 1 0 0 32
PASH 14 0 0 0 14
Papilloma* 7 3 0 0 10
Lymph node 5 0 0 0 5
Total 328 77 34 48 487
Note: Numbers are numeric
* solitary papilloma without atypia
DCIS, ductal carcinoma in situ
PASH, pseudoangiomatous stromal hyperplasia
FAH, fibroadenomatoid hyperplasia
VABB, vacuum assisted breast biopsy
Fig. 2 A 44-year-old woman
with a suspicious, segmental non-
mass lesion classified as BI-
RADS 4. a: Pre-contrast scan
showing the biopsy marker in its
basic position. b: early contrast-
enhanced T1-weighted subtrac-
tion depicting a heterogeneous
segmental non-mass lesion. c:
control scan immediately before
MRI-guided VABB with the bi-
opsy marker indicating a correct
positioning. d: subtraction corre-
sponding to c. Histopathology re-
vealed a high risk lesion (ADH,
atypical ductal hyperplasia). The
patient underwent subsequent
surgery where small nests of
DCIS G2 were identified
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that the majority of malignant lesions could be detected by
second-look ultrasound. Nevertheless, even if second-look ul-
trasound is negative, there is a low, but significant, probability
of malignancy. As we subsequently applied second-look ul-
trasound in our department, the rate of malignancy in this
cross-sectional study was decreased compared to a setting in
which second-look ultrasound is not used consistently [3].
AlthoughMR-guided VABB is considered an accurate and
safe method, CE-MRI of the breast leads to false-positive
results in up to 74.1 % [30]. This fact underlines the need
for improved lesion differentiation between benign and ma-
lignant lesions to reduce unnecessary biopsies, and to improve
the overall accuracy of CE-MRI of the breast. Recently, a
study has reported that the addition of diffusion-weighted im-
aging (DWI) of the breast enables a reduction in false-posi-
tive, MR-guided biopsies by >30 % [30]. This is in good
agreement with recently published results of multiparametric
MRI of the breast, which resulted in a high diagnostic accu-
racy for MRI of breast tumours of [31, 32] and highlights the
clinical usefulness of this technique in supporting a diagnosis.
Previous studies reported that MR-guided biopsy is not
possible in up to 3 % of cases [7, 13, 18]. In the current study,
we did not experience that, due to strict selection criteria for
MR-guided VABB, and second-look ultrasound was routinely
performed. In all cases, imaging data were reviewed before
MR-guided VABB was scheduled. If the successful perfor-
mance of an MR-guided VABB was in doubt, i.e. close to
the nipple or chest wall, a treatment decision for either MR-
guided VABB or MR-guided wire localization was reached in
a multidisciplinary conference.
We provide the first empirical data on false negative and
underestimation rates using three different VABB devices un-
der the same clinical conditions, though this study is not free
of limitations. The majority of benign findings had only im-
aging follow-up. However, in accordance with previous stud-
ies, we have used a minimum of 12 months of follow-up to
establish a standard of reference [21, 22]. A further limitation
of our study is that we did not report data on the intervention
time of each device. Nevertheless, a previous study has al-
ready proven that console-based biopsy systems allow MR-
guided VABB in shorter intervention times, compared to
hand-held devices [16]. Finally, numerical differences were
in favor of the MR-guided, console-based vacuum biopsy
system A (Table 2). However, they did not reach statistical
significance when compared to M (console-based) and V
(hand-held). This trend is in concordance with previous data
showing higher accuracy for console-based (100 %) than
Table 4 Characteristics of 11 cases of false-negative MR-guided
VABB results
























Note: Numbers in parentheses are percentages
DCIS, ductal carcinoma in situ
NME, non mass enhancement
VABB, vacuum assisted breast biopsy
Fig. 3 a: A 41-year-old woman with an ill-defined mass lesion in the
right breast classified BI-RADS 4. b: During intervention, the planing
scan shows a seemingly correct position of the biopsy marker.
Histopathology revealed benign breast tissue classified as B1. This case
was rated discrepant as histology could not explain a solid lesion. c:
Consequently, another MRI scan was performed after 2 weeks, showing
the post-biopsy clip in a lateral position while the biopsied lesion was
untouched. Re-biopsy revealed an IDC G2
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hand-held (98%) systems [16]. In addition previously, the soft
endpoint, operator confidence, appeared to be higher in
console-based vacuum biopsy systems [16].
In conclusion, MR-guided VABB is an accurate procedure
for the diagnosis of MRI-only lesions. There was no influence
of the three different biopsy devices used on false-negative
and underestimation rates. In case of radio-histopathological
discordance (Fig. 3), repeat or surgical biopsy is recommend-
ed to avoid false-negative results. High-risk lesions should
undergo subsequent surgery due to a substantial high-risk le-
sion underestimation rate.
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